Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, ...

Ken Hall looks at two big investment risks that are keeping him up at night as we enter 2025 with the UK stock market ...

Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, ...

Birmingham-based global coaching and training business, OTD, has announced the appointment of Rebecca Farnworth as managing ...

GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy ...

RNA is a long, polymeric molecule, composed of four different building blocks called nucleotides. In the last decade mRNA has progressed into a promising new class of medicine, with the potential to ...

True economic revival will require more than marginal improvements in specific sectors; it demands a holistic transformation ...

The FTSE 100 is flat and European stocks are up, while Wall Street has seen a U-turn, with the tech-heavy Nasdaq now leading ...

GSK has selected a site currently being constructed on the corner of New Oxford Street and Earnshaw Street – known as the Earnshaw building – for its new HQ, which is currently located to the ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

Our fair value estimate for WuXi is HKD 24.60 per share. WuXi has been growing at a CAGR of 53.3% for the past eight years. Although its USD 20.5 billion total backlog revenue supports our growth ...

A UK biotechnology startup is entering the crowded obesity drug market, armed with $411 million and a promising ...